ERF logo

Eurofins Scientific SE Stock Price

ENXTPA:ERF Community·€10.9b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 32 Fair Values set on narratives written by author

ERF Share Price Performance

€61.78
4.32 (7.52%)
€70.74
Fair Value
€61.78
4.32 (7.52%)
12.7% undervalued intrinsic discount
€70.74
Fair Value
Price €61.78
AnalystConsensusTarget €70.74
AnalystHighTarget €86.00
AnalystLowTarget €48.00

ERF Community Narratives

·
Fair Value €70.74 12.7% undervalued intrinsic discount

Digitalization And Automation Will Unlock Future Diagnostics Potential

0users have liked this narrative
0users have commented on this narrative
20users have followed this narrative
·
Fair Value €86 28.2% undervalued intrinsic discount

Digital Investments And Rising Safety Mandates Will Expand Advanced Diagnostics

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value €48 28.7% overvalued intrinsic discount

Automation And Regulatory Hurdles Will Erode Traditional Lab Margins

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
€86
28.2% undervalued intrinsic discount
Revenue
8.67% p.a.
Profit Margin
10.31%
Future PE
18.96x
Price in 2029
€105.68
€70.74
12.7% undervalued intrinsic discount
Revenue
5.93% p.a.
Profit Margin
9.16%
Future PE
18.97x
Price in 2029
€87.03

Trending Discussion

Updated Narratives

ERF logo

ERF: Expanded Hantavirus Testing Network Will Support Re Rating Potential

Fair Value: €86 28.2% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ERF logo

ERF: Buyback Plans And Updated Assumptions Will Support Future Upside Potential

Fair Value: €70.74 12.7% undervalued intrinsic discount
20 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ERF logo

ERF: Higher Discount Rate Will Pressure Execution And P/E Re Rating

Fair Value: €48 28.7% overvalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with moderate growth potential.

2 Risks
4 Rewards

Eurofins Scientific SE Key Details

€7.3b

Revenue

€5.7b

Cost of Revenue

€1.6b

Gross Profit

€1.2b

Other Expenses

€416.1m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
2.37
22.49%
5.70%
87.3%
View Full Analysis

About ERF

Founded
1987
Employees
65694
CEO
Gilles Martin
WebsiteView website
www.eurofins.com

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product testing, which include sustainability, testing, certifications and approvals, expert services and regulatory, inspections, audits, consumer research and sensory evaluation, and training courses; cosmetics and personal care; and electrical and electronics laboratories services. In addition, it provides environment testing, including maritime, water, air, soil, building material, pollution, waste, fuel/oil, microplastics, and radioactivity testing; and food and feed testing that include allergen, audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, GMO, heavy metal, melamine, microbiology, molecular biology, mycotoxin, nutritional analyses, organic contaminants, pesticide, veterinary drug, vitamin, and residual DNA testing. Further, the company provides forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services, as well as in vitro diagnostics and PSS insourcing solutions. The company was founded in 1987 and is headquartered in Luxembourg, Luxembourg.

Recent ERF News & Updates

Narrative Update May 29

ERF: Expanded Hantavirus Testing Network Will Support Re Rating Potential

Analysts have trimmed their price target on Eurofins Scientific from €93 to €86, reflecting updated assumptions around fair value, revenue growth, profit margins, and future P/E multiples. What's in the News Eurofins companies are monitoring a hantavirus outbreak linked to a cruise ship, with 11 reported cases and 3 deaths associated with the Andes strain, and are positioning existing testing capabilities to address potential demand across multiple countries (Key Developments).
Narrative Update May 12

ERF: Buyback Plans And Updated Assumptions Will Support Future Upside Potential

Analysts have nudged their price target for Eurofins Scientific slightly lower from about €71.71 to roughly €70.74, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News A board meeting is scheduled for April 23, 2026, to consider shares to be purchased under a new buyback programme, which could affect the share count and capital allocation plans (Key Developments).

Recent updates

No updates